ArticleEnvironment international2022
A computational system for Bayesian benchmark dose estimation of genomic data in BBMD.
Article in Environment international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Review on Predictive Models and Integration Strategies for Holistic Impact Assessment of Chemicals and Materials.Environmental science & technology · 2026Review
- Article
- BayesCurveFit: Enhancing Curve Fitting for Early-Stage Compound Screening Using Bayesian Inference.bioRxiv : the preprint server for biology · 2025Article
- Comparison of in utero phthalate exposure on fetal rat testis transcript and endocrine alterations with apical reproductive alterations in male rats.Toxicology and applied pharmacology · 2025Article
- Bioinformatic workflows for deriving transcriptomic points of departure: current status, data gaps, and research priorities.Toxicological sciences : an official journal of the Society of Toxicology · 2025Review
- The use of canonical dose-response models for benchmark dose analysis of continuous toxicological data.Critical reviews in toxicology · 2025Review
- Article
- Exploring the effects of experimental parameters and data modeling approaches on in vitro transcriptomic point-of-departure estimates.Toxicology · 2024Article
- Quantitative Integration of Mode of Action Information in Dose-Response Modeling and POD Estimation for Nonmutagenic Carcinogens: A Case Study of TCDD.Environmental health perspectives · 2023Article
- A mode of action-based probabilistic framework of dose-response assessment for nonmutagenic liver carcinogens: a case study of PCB-126.Toxicological sciences : an official journal of the Society of Toxicology · 2023Article
- The Effect of Historical Data-Based Informative Prior on Benchmark Dose Estimation of Toxicogenomics.Chemical research in toxicology · 2023Article
- Using Prior Toxicological Data to Support Dose-Response Assessment─Identifying Plausible Prior Distributions for Dichotomous Dose-Response Models.Environmental science & technology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundExisting studies have revealed that the benchmark dose (BMD) estimates from short-term in vivo transcriptomics studies can approximate those from long-term guideline toxicity assessments. Existing software applications follow this trend by analyzing omics data through the maximum likelihood estimation and choosing the "best" model for BMD estimates. However, this practice ignores the model uncertainty and may result in over-confident inferences and predictions, leading to an inadequate decision.
objectiveBy generally following the National Toxicology Program Approach to Genomic Dose-Response Modeling, we developed a web-based dose-response modeling and BMD estimation system, Bayesian BMD (BBMD), for genomic data to quantitatively address uncertainty from various sources. The performances of BBMD are compared with BMDExpress.
methodsThe system is primarily based on the previously developed BBMD system and further developed in a genomic perspective. Bayesian model averaging method is applied to BMD estimation and pathways analyses. Generally, the system is unique regarding the flexibility in preparing/storing data and in characterizing uncertainties.
resultsThis system was tested and validated versus 24 previously published in-vivo microarray dose-response datasets (GSE45892) and 64 molecules data from the Open TG-Gates database. Short term transcriptional BMD values for the median pathway in BBMD are highly correlated with the long-term apical BMD values (R = 0.78-0.91). The BMD estimates obtained by BBMD were compared to those by BMDExpress. The results indicate that BBMD provides more adequate results in terms of less extreme values and no failure in BMD and BMDL calculations. Also, the pathway analysis in BBMD provides a conservative estimate because a broader confidence interval is established. DISCUSSION: Overall, this study demonstrates that dose-response modeling using genomic data can play a substantial role in support of chemical risk assessment. BBMD represents a robust and user-friendly alternative for genomic dose-response data analysis with outstanding functionalities to quantify uncertainty from various sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.